Philogen S.p.A.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Philogen S.p.A. sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Philogen S.p.A.: 7 sponsored US clinical trials, 4 recruiting.
Philogen S.p.A. sponsors 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Melanoma Stage IIID, with 1 trials.
Upper-quartile sponsor footprint
Philogen S.p.A. sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
NCT07227350
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
NCT06284590
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
NCT06336291
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
NCT03567889
Dose Finding Study of L19TNF and Doxorubicin in Patients With STS
NCT04032964
L19IL2/TNF in Patients With Basal Cell Carcinoma
NCT07227870
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
NCT07228442
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Philogen S.p.A. pipeline
4 recruiting of 7 indexed (57% open).
Phase mix: 1 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Melanoma Stage IIID (1 trial), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Philogen S.p.A.: open-pipeline peers nationwide
Peers matched on 7 registered trials and 57% open enrollment, not the therapeutic-area sidebar.
Philogen S.p.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 57% open enrollment (± trial volume)
- Alimentiv · 57% recruiting · 7 trials
- Aura Biosciences · 57% recruiting · 7 trials
- BicycleTx Limited · 57% recruiting · 7 trials
- Binghamton University · 57% recruiting · 7 trials
Related
What to do with this Philogen S.p.A. page
7 registered trials is a research-attention snapshot, not an endorsement of Philogen S.p.A. or any single study.
- 4 of Philogen S.p.A.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Melanoma Stage IIID is the condition Philogen S.p.A. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Melanoma Stage IIID trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Philogen S.p.A. pipeline card: 7 registered trials from official public datasets.Report a data error.